Elan

Perrigo to acquire Elan for $8.6 billion

Monday, July 29, 2013 11:02 AM

Allegan, Mich.-based Perrigo, a global provider of healthcare products and Elan, a Dublin-based biotechnology company, have entered into a definitive agreement under which Elan will be acquired by a new holding company incorporated in Ireland (“New Perrigo”).

More... »

Royalty Pharma’s offer lapses, withdraws judicial review

Wednesday, June 19, 2013 01:38 PM

Royalty Pharma has withdrawn its request for a judicial review of the Irish Takeover Panel's decision that required it to lapse its offer for Elan once shareholders approved its Share Repurchase Program at a special shareholders’ meeting Monday. Shareholders approved a $200 million share buyback.

More... »

Elan shareholders approve one of four transactions

Monday, June 17, 2013 03:30 PM

Elan shareholders approved one of four transactions up for a vote at its special meeting Monday. Shareholders rejected plans for a $1 billion cash acquisition of a 21% stake in Theravance’s royalties from the respiratory franchise it shares with GSK; acquisition of Vienna, Austria-based AOP Pharmaceuticals for $348.8 million; and the spinout of ELND005 into a new Irish startup Speranza Therapeutics, with $70 million in funding.

More... »

Elan to proceed with formal sale process

Friday, June 14, 2013 02:38 PM

Elan has announced it is proceeding with a formal sale process in light of the expressions of interest received to date. As part of this process, Royalty Pharma will be invited to participate. Elan has urged shareholders not to tender into the current Royalty Pharma offer.

More... »

Elan announces transactions to transform the company

Wednesday, May 22, 2013 10:42 AM

Elan, a biotechnology company based in Ireland, announced a series of transactions designed to decisively transform and advance the company. Upon shareholder approval, the totality of these strategically driven decisions, in addition to the Theravance royalty participation agreement, the dividend pass through, and the completed Tysabri transaction, will form a dynamic and unique business foundation for Elan in the years ahead.

More... »

Elan CEO says $1 billion royalty deal with Theravance a unique opportunity

Tuesday, May 14, 2013 01:12 PM

Elan has announced a royalty agreement with Theravance, by which Elan will make a one-time cash payment of $1 billion to Theravance in exchange for a 21% participation interest in the potential future royalty payments from four respiratory programs for which Theravance has partnered with GlaxoSmithKline, when and if received by Theravance.

More... »

Royalty Pharma makes firm offer to acquire Elan

Tuesday, April 16, 2013 09:41 AM

Echo Pharma Acquisition (Royalty Pharma) announced the terms of a firm, all cash offer for the entire issued and to be issued share capital of Elan. 

More... »

Elan closes Tysabri collaboration transaction with Biogen Idec

Wednesday, April 3, 2013 03:17 PM

Elan, a biotechnology company based in Ireland, has closed its Tysabri (natalizumab) collaboration transaction with Biogen Idec, which was originally announced on February 6, 2013.

More... »

Elan acknowledges Royalty’s proposal

Monday, February 25, 2013 10:57 AM

The board of Elan, a biotechnology company based in Ireland, has acknowledged the announcement by Royalty Management regarding an indicative, conditional, proposal which may or may not lead to an offer being made for the entire issued share capital of Elan.

More... »

Biogen Idec acquires full rights of Tysabri from Elan

Wednesday, February 6, 2013 11:41 AM

Biogen Idec, an independent biotechnology company, has agreed to purchase biotech Elan’s full strategic, commercial and decision-making rights to Tysabri.

More... »